Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin ...

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Stifel has launched its coverage on pre-clinical stage biotech Oruka Therapeutics (NASDAQ:ORKA) with a buy recommendation and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002.

Traders use this information to analyze potential trades and assess market sentiment for Oruka Therapeutics. In The Money Expiration Date December 20, 2024 March 21, 2025 ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...